When they do die, it's more likely to be their heart.
Over sixteen years, researchers following nearly ten thousand female competitive bodybuilders found that sudden cardiac death claimed more lives than any other cause — striking women at a mean age of 43, most often near the time of competition. Published in the European Heart Journal, the study reveals that while female bodybuilders die less frequently overall than their male counterparts, the cardiac gap between the sexes narrows in troubling ways when the cause is the heart itself. The findings place a quiet but urgent question before the sporting and medical world: what is the female heart being asked to endure, and at what cost?
- Ten of 32 documented deaths were sudden cardiac events, making heart failure the leading killer in a cohort of nearly 10,000 female athletes tracked across 16 years.
- Professional female bodybuilders faced a sudden cardiac death rate of 54 per 100,000 athlete-years — more than twenty times that of amateurs — with deaths clustering ominously close to competition dates.
- A paradox unsettles the data: women die overall at roughly half the rate of male bodybuilders, yet their cardiac death risk is only 57% lower, suggesting the female heart bears a disproportionate share of the sport's fatal toll.
- Only two autopsies were performed among professional women who died, leaving the underlying cardiac mechanisms — and the role of performance-enhancing drugs — largely unconfirmed and scientifically unresolved.
- Researchers are now calling for mandatory cardiac screening, stricter PED regulation, and deeper investigation, while acknowledging that a quarter of all deaths in the study remain without any determined cause.
Between 2005 and 2020, a team of researchers followed 9,447 female bodybuilders competing in international events across three divisions — Women's Bodybuilding, Women's Physique, and Figure. Of the 32 deaths documented over that period, ten were sudden cardiac events, making cardiac failure the single leading cause of death in the group. The mean age at death was 43 years, and nearly half the deaths occurred among North American athletes.
The risk was far from uniform. Professional athletes faced a sudden cardiac death rate of 54 per 100,000 athlete-years, compared to just 2.5 among amateurs. Seven deaths occurred within a year of a woman's last competition, and both sudden cardiac deaths in that subgroup happened near competition dates — a pattern pointing toward the sport's peak demands, or the methods athletes use to meet them, as potential triggers.
Compared to male bodybuilders studied in parallel, women showed roughly half the overall mortality. Yet when researchers looked specifically at cardiac deaths, the gap narrowed considerably — women's rate was only 57% lower than men's, and among professionals, the disparity shrank further. The female heart, it appears, bears a disproportionate share of the sport's fatal burden. The limited autopsy data offered little clarity: one of the two professional women autopsied had a normal heart; the other showed myocarditis. Male bodybuilders, by contrast, frequently displayed structural changes such as enlarged hearts or thickened ventricular walls.
Performance-enhancing drugs are a suspected but largely unconfirmed factor — toxicological analysis confirmed PED use in only four cases. A quarter of all deaths had no determined cause. The study also noted that suicide and homicide accounted for roughly 13% of deaths among female bodybuilders, more than four times the rate seen in males, hinting at psychosocial pressures that extend well beyond the physical demands of the sport.
The researchers conclude that the cardiac risk facing female competitive bodybuilders is real, measurable, and distinct from that of other female athletes — and that without more rigorous autopsies, broader toxicological screening, and tighter medical oversight, the mechanisms driving these deaths will remain dangerously obscure.
Between 2005 and 2020, researchers tracking 9,447 female bodybuilders across international competitions documented 32 deaths. Ten of those deaths were sudden cardiac events—the leading cause of mortality in the group. The finding, published in the European Heart Journal, raises urgent questions about what happens to the female heart under the extreme physical demands of competitive bodybuilding.
The study followed women competing in three divisions: Women's Bodybuilding, Women's Physique, and Figure. Researchers sorted athletes by age category, professional or amateur status, and division type, then calculated death rates per 100,000 athlete-years. The mean age at death was 43 years. Nearly half the deaths occurred among North American athletes. Of the 32 total deaths, 24 had a documented cause. Among those, sudden cardiac death accounted for roughly a third—ten women whose hearts simply stopped, typically around the time of competition.
The risk was not evenly distributed. Professional female bodybuilders faced a sudden cardiac death rate of 54 per 100,000 athlete-years, compared to 2.5 per 100,000 among amateurs. The Women's Bodybuilding division showed the highest incidence. Currently competing athletes experienced even steeper rates. Seven deaths occurred within a year of a woman's last competition, and both sudden cardiac deaths in that group happened near competition dates. The pattern suggests that the demands of the sport itself—or the practices athletes use to meet those demands—may be triggering fatal events.
When researchers compared these findings to a parallel study of male bodybuilders, a paradox emerged. Women had roughly half the overall mortality rate of men. Yet their sudden cardiac death risk was only 57 percent lower, meaning the gap narrowed considerably when looking specifically at cardiac events. Among professionals, the difference was starker: women's sudden cardiac death rate was 28 percent that of men. This suggests that while female bodybuilders die less often overall, when they do die, cardiac failure plays a disproportionate role.
The autopsies offered limited insight. Only two of the professional women who died underwent autopsy—one showed a normal heart, the other myocarditis, an inflammation of the heart muscle. In contrast, male bodybuilders who died often displayed structural changes like enlarged hearts or left ventricular hypertrophy, thickening of the heart's main pumping chamber. Whether female hearts respond differently to the same training and drug regimens, or whether the women in this cohort faced different risk factors, remains unclear.
Performance-enhancing drugs loom as a likely culprit. Extreme strength training, rapid weight-cutting before competitions, and PED abuse are documented risks in male bodybuilders and almost certainly present in the female population as well. Yet the study confirmed PED use in only four cases through toxicological analysis. The researchers could not quantify how much each risk factor contributed to the deaths. A quarter of all deaths had no determined cause at all, a significant gap in understanding.
One other finding stood out: suicide and homicide accounted for roughly 13 percent of deaths among female bodybuilders—more than four times the rate seen in male bodybuilders. The researchers noted that qualitative research has documented greater psychosocial vulnerability and gender-specific stressors in female bodybuilding, though the study could not establish causality. The observation hints at pressures beyond the physical.
The study's scope was large and its duration substantial, yet crucial questions remain unanswered. Without more autopsies, without toxicological screening in all cases, without adjustment for confounding factors, the precise mechanisms driving sudden cardiac death in female bodybuilders stay obscured. What is clear is that the risk exceeds that of other female athletes and demands attention—tighter medical screening, stricter regulation of performance-enhancing drug use, and a deeper investigation into why the female heart appears uniquely vulnerable to the demands of competitive bodybuilding.
Citas Notables
Sudden cardiac death was the most common cause of death in both male and female bodybuilders, though incidence in women was 57% lower overall and 28% lower among professionals.— European Heart Journal study findings
La Conversación del Hearth Otra perspectiva de la historia
Why does sudden cardiac death show up as the leading cause when overall mortality is actually lower in women than men?
The numbers are counterintuitive, but they tell you something real. Women die less often overall, but when they do die, it's more likely to be their heart. That suggests the sport itself—or what athletes do to compete—may be triggering cardiac events specifically, even if other causes of death are less common.
The autopsy data seems thin. Only two autopsies among professional women who died?
Exactly. Two autopsies out of dozens of deaths is almost nothing. You can't see what actually killed the heart without looking inside it. The male bodybuilders in the comparison study showed enlarged hearts and thickened chambers—structural changes. The two women autopsied showed different patterns. But with such limited data, you're essentially guessing about what's happening.
Performance-enhancing drugs are mentioned as a likely culprit, but confirmed in only four cases. How do you reconcile that?
The researchers know PEDs are almost certainly involved in many more deaths than four. But they can only confirm what toxicology screens show. Most bodies aren't screened. It's a gap between what they suspect and what they can prove, and it's a big one.
The suicide and homicide rate is four times higher than in male bodybuilders. What does that suggest?
It points to something beyond the physical. Female bodybuilders face different social pressures, different standards, different scrutiny. The study mentions prior research on psychosocial vulnerability and gender-specific stressors. The numbers suggest those pressures may have real consequences, though the study itself can't prove causation.
Does this mean women shouldn't bodybuilding?
No. It means the sport needs oversight. Medical screening before competition, regulation of drug use, monitoring during the season. The risk is real and concentrated—especially among professionals and during competition windows. That's actionable information.